Current management of patients with severe PAH and New York Heart Association/World Health Organization (NYHA/WHO) class IV symptoms includes use of MR antagonists once clinical right heart failure has developed for their diuretic and natriuretic effects [27]. Here, NR3C2 is linked to pulmonary arterial hypertension.